Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial Evaluating Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay020 in Patients With Advanced Solid Cancer

Next Previous
Trial Profile

Phase I Trial Evaluating Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay020 in Patients With Advanced Solid Cancer

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hemay 020 (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Tianjin Hemay Biotech

Most Recent Events

  • 29 Feb 2024 Status changed from recruiting to discontinued.
  • 25 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
  • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top